Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive antagonist of histamine at the H2 receptor on gastric parietal cells, reducing gastric acid secretion (basal and stimulated).
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Treatment of active duodenal ulcer,Prophylaxis of recurrent duodenal ulcer,Treatment of active benign gastric ulcer,Prophylaxis of gastric ulcer in patients at risk,Treatment of gastroesophageal reflux disease (GERD),Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome),Prophylaxis of stress ulcer in critically ill patients,Prevention of aspiration pneumonitis during anesthesia (off-label),Treatment of urticaria (off-label)
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
300 mg IV every 6-8 hours, or as a continuous IV infusion of 37.5 mg/hour (900 mg/day) for patients unable to take oral therapy.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Terminal elimination half-life: approximately 2 hours in healthy adults; prolonged in renal impairment (up to 20 hours in anuria).
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Hepatic metabolism via N-oxidation, S-oxidation, and demethylation; major pathway is N-oxidation. CYP450 involvement is minimal; primarily metabolized by flavin-containing monooxygenase (FMO3).
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: 70% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minor (approximately 10-15% as metabolites).
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
13-25% bound to plasma proteins (primarily albumin).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
1.0-2.0 L/kg; large Vd indicates extensive tissue distribution (e.g., muscle, kidney, liver).
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Oral: 60-70% (due to first-pass metabolism); intravenous: 100%.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
For Cr Cl 30-50 m L/min: 300 mg IV every 8 hours. For Cr Cl 15-29 m L/min: 300 mg IV every 12 hours. For Cr Cl <15 m L/min: 300 mg IV every 24 hours.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific adjustment for Child-Pugh; use caution and reduce dose in severe hepatic impairment based on clinical response, as clearance may be decreased.
No dosage adjustment required for hepatic impairment.
Neonates: 5-10 mg/kg IV every 8-12 hours. Infants and children: 5-10 mg/kg IV every 6-8 hours, not to exceed 300 mg per dose. Adolescents: 300 mg IV every 6-8 hours.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Reduce dose based on renal function; start at lower end of dosing range (e.g., 300 mg IV every 12 hours if Cr Cl 30-50 m L/min) and titrate to response. Monitor for CNS side effects.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
May cause confusion, hallucinations, or delirium (especially in elderly, renally impaired, or critically ill patients),May cause hepatotoxicity (elevated liver enzymes, hepatitis),May cause bone marrow suppression (neutropenia, agranulocytosis; rare),May cause bradycardia or cardiac arrhythmias with rapid IV administration,May inhibit cytochrome P450 (CYP1A2, CYP2C19, CYP2D6, CYP3A4) leading to increased levels of coadministered drugs (e.g., warfarin, theophylline, phenytoin),May cause gynecomastia or impotence with prolonged high doses,Use with caution in patients with renal impairment (dose adjustment required)
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to cimetidine or any component of the formulation,Use in patients with porphyria (may precipitate acute attacks),May interfere with vitamin B12 absorption (long-term use associated with deficiency)
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Cimetidine may increase absorption of alcohol, leading to higher blood alcohol levels. Avoid alcohol. High-fat meals may slightly decrease absorption, but not clinically significant. No specific food restrictions.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Cimetidine crosses the placenta. First trimester: Limited data; no increased risk of major malformations in prospective studies. Second/third trimester: No consistent evidence of fetal harm, but cimetidine has been associated with transient neonatal hepatic impairment and antiandrogenic effects in animal studies (dose-dependent). Use only if clearly needed.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Cimetidine is excreted into human breast milk (M/P ratio approximately 0.7). Peak milk levels occur 1-2 hours after dose. Milk levels are ~10-20% of maternal serum levels. Dose equivalent to infant is about 6-10% of maternal weight-adjusted dose. Caution: potential for anticholinergic effects in the infant. Monitor infant for drowsiness, bradycardia, or hypotonia. Alternative agents (e.g., ranitidine) are preferred.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No pharmacokinetic-specific dose adjustments are standard for cimetidine in pregnancy. However, due to increased renal clearance in pregnancy and possible altered hepatic metabolism, consider dosing at the lower end of the effective range (e.g., 300 mg IV q6-8h) and monitor therapeutic response. For continuous infusion, consider dose reduction in renal impairment.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Cimetidine is a potent inhibitor of CYP1A2, CYP2C19, CYP2D6, and CYP3A4, leading to increased serum levels of many drugs including warfarin, theophylline, phenytoin, and lidocaine. In elderly or renally impaired patients, reduce dose to prevent CNS side effects like confusion or hallucinations. Rapid IV administration can cause hypotension or cardiac arrhythmias; infuse over at least 30 minutes. Monitor for elevated serum creatinine initially due to interference with tubular secretion of creatinine.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Do not smoke while taking this medication, as smoking can decrease its effectiveness.,Avoid alcohol consumption, which can worsen stomach irritation.,Inform your doctor about all medications you take, as cimetidine can interact with many drugs.,Report any confusion, dizziness, or unusual bleeding/bruising immediately.,Take exactly as prescribed; do not increase the dose without consulting your healthcare provider.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Competitive antagonist of histamine at the H2 receptor on gastric parietal cells, reducing gastric acid secretion (basal and stimulated).. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 300 mg IV every 6-8 hours, or as a continuous IV infusion of 37.5 mg/hour (900 mg/day) for patients unable to take oral therapy.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Cimetidine crosses the placenta. First trimester: Limited data; no increased risk of major malformations in prospective studies. Second/third trimester: No consistent evidence of f. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.